TRAIL, a type-II transmembrane homotrimeric protein that belongs to the TNF gene superfamily, is a promising candidate for cancer therapy because of its selective apoptotic effect in a wide variety of transformed cells without affecting normal cells.
Combined treatment with NP-TRAIL and g-radiation or bortezomib sensitized TRAIL-resistant GSCs to NP-TRAIL.